Abstract
The C282Y mutation
In the HFE C282Y mutation a single-base transition leads to the substitution of a tyrosine for a cysteine at position 282. This provokes the disruption of the ␣3 domain intrachain disulfide bond, which is a mandatory pre-requisite for ␤2m association, intracellular transport and expression of HFE at the cell surface. As a result, the C282Y mutant protein does not fold correctly and fails to bypass the endoplasmic reticulum (ER) quality control mechanisms being trapped in this compartment and subjected to premature proteasomal degradation [3, 4] (Fig. 1) . Recently it was observed that this mutant protein forms intracellular aggregates in vitro [5] . The formation of protein aggregates caused by destabilization of the ␣-helical structure with simultaneous formation of a ␤-sheet is a common feature of almost all diseases of protein conformation [6] . These aggregates tend to resist degradation and accumulate in inclusion bodies [7] and, although their identity and contribution to disease progression are largely unknown, collected evidence suggests that they may be toxic [8] .
Another common HFE mutation, the H63D mutation, whose pathogenic significance is still uncertain, involves the substitution of a histidine by an aspartate at position 63 . This mutation occurs in the ␣1 domain of the protein and does not perturb ␤2m association or intracellular localization of the HFE protein [2, 9] . [10] . The pancreas, heart, skin, joints and particularly the liver are the main deposition sites where the iron surplus leads to organ failure through the production of oxidant species. Cirrhosis, hepatocellular carcinoma, cardiomyopathy, diabetes and arthritis are some of the pathologies associated with chronic iron overload [11] . Nevertheless [14] . Adding to the evidence of an implication in iron metabolism, shortly after its discovery HFE was found to associate with the transferrin receptor 1 (TfR1) [15] and to decrease its affinity for iron-bound transferrin by 5 to 10-fold [16] . The C282Y mutation disrupts this association, thus preventing HFE's inhibitory role on iron uptake [16] . Besides this impairment of iron uptake, HH is also characterized by defects of the iron export machinery and poor iron storage in reticuloendothelial cells. HFE blocks cellular iron export from macrophages a function lost in HH because of the C282Y mutation [17] .
HFE and hereditary haemochromatosis

Hereditary haemochromatosis (HH) is the most common inherited disease in Caucasians. In these patients, intestinal iron absorption and iron export from macrophages are abnormally elevated resulting in progressive tissue iron overload which leads to irreversible organ damage if not treated timely
HFE's role in the regulation of cellular iron stores and, more significantly, the impact of the C282Y mutation on this task definitely implicated this particular mutation on the physiopathology of HH. [27, 28] . Upon ␤2m association, calnexin is replaced by calreticulin and the heterodimer is recruited to a multi-subunit structure, collectively termed the PLC, containing, at least, tapasin, calreticulin, ERp57 and the transporter associated with antigen presentation (TAP) [29] .
Immunological abnormalities of HH patients
Designing a peptide loaded MHC-I protein
Although conceptually simple, the aim being to display a fingerprint of the intracellular content at the cell surface by means of small protein fragments, antigen presentation is a rather sophisticated process involving a number of crucial events: MHC-I folding and maturation, peptide generation and shuttle into the ER, assembly of the peptide loading complex (PLC), trafficking of peptide loaded MHC-I to the cell surface and ultimately its recognition by CD8 + T lymphocytes (Fig. 2). MHC-I antigen presentation is initiated in the ER where folding of MHC-I molecules takes place. This is a complex process, which involves the participation of a variety of auxiliary factors, like heavy-chain binding protein (BiP -also termed GRP78), the lectin chaperones calnexin and calreticulin, and the oxidoreductase ERp57 [26]. Following translocation into the ER via the Sec61 protein complex, MHC-I heavy chains (HC) bind to the chaperones BiP and calnexin and associate non-covalently with the soluble ␤2m
The newly generated peptide-receptive MHC-I molecules are recruited into the PLC where they are stabilized until peptide loading takes place. A heterodimer of two membrane-spanning molecules, termed TAP1 and TAP2 translocates the peptides from the cytosol to the ER lumen, where loading onto MHC-I molecules takes place [30, 31] . This process favours the production of stable MHC-I/peptide complexes [32] . [35] .
MHC-I molecules that fail to acquire high-affinity peptides exit the ER from a site distinct from that used by high-affinity MHC-I/peptide complexes, and are subjected either to degradation or short term expression at the cell surface followed by endocytosis and degradation [36] . MHC-I molecules, once loaded with high-affinity peptides, dissociate from the PLC, leave the ER at specific exit sites, transit through the Golgi apparatus, and emerge at the cell surface [37] 
Hijacking MHC-I: viruses take control
The fact that the main source of peptides for MHC-I scrutiny are DRiPs enables the immune surveillance mechanisms to detect pathogens that employ the host cell for protein synthesis [40, 43] [44, 45] .
HFE C282Y influences the MHC-I antigen presentation pathway
Even though previous findings strongly suggested an extended role related to the immune system, evidence for a direct impact of HFE on a classical immunological process was described only recently. A thorough analysis of the MHC-I antigen presentation pathway revealed the existence of significant differences between HFE C282Y mutant cells obtained from HH patients and HFE wt cells. Several corrupted intracellular events lead to the generation of high off-rate MHC-I/peptide complexes that dissociate prematurely during their journey towards the cell surface. The outcome is a diminished surface expression of MHC-I molecules in HFE C282Y mutant cells [46]. Although not yet tested, the key role exerted by MHC-I molecules in a number of processes suggests that this defect may have a considerable physiological significance. In view of that, a correlation between this observation and the recognized immunological defects linked to HH may be discussed.
Signallingby [56] .
MHC-I plays an inhibitory role in the shaping of the NK cells' response. An insufficient signallingby MHC-I-specific inhibitory receptors present on NK cells triggers their activation and cytotoxicity against cells that are either MHC-I negative or deficient [51]. The decreased cell surface expression of MHC-I molecules in HFE mutant cells makes them suitable candidates for targeting by NK cells. There is evidence that down-regulation of MHC-I on resting lymphocytes was sufficient to make them susceptible to NK cell killing [53]. HFE itself does not inhibit or activate the activity of NK cells [54], but by affecting MHC-I expression, HFE C282Y mutant cells may become particularly suitable targets of NK cytotoxicity. In another study performed with transgenic mice, it was observed a direct cytolytic recognition of human HFE by mouse T cell receptors (TCR), which occurs independently of HFE-bound peptides [55]. This new function of HFE is in agreement with the previous finding that TCR-delta knockout mice develop hepatic iron overload suggesting that cellular iron status might be transmitted to lymphocytes through HFE engagement with the TCR
The findings that mouse TCR directly recognize human HFE independently of HFE-bound peptides [55] and that HFE C282Y impacts on the MHC-I expression [46] [60] . [63] (Fig. 3) .
provided evidence for the involvement of HFE on classical immunological mechanisms. In fact, with the exception of HFE and zinc-␤2-glycoprotein [57-59], all the non-classical MHC-I molecules have previously been shown to be directly involved in immunological processes
Collateral damages or selective interference? The UPR effect on MHC-I expression
By preventing HFE association with ␤2m, the C282Y mutation causes the ER retention of HFE [4, 9] . [64] . A strong link between the UPR and the MHC-I antigen presentation pathway defects was established. However, this association was found to prevail beyond the mere significance for the HH associated MHC-I defects. Regardless of the ER stress stimuli tested, it was noted that activation of the UPR consistently provokes a significant collapse of the MHC-I processing apparatus resulting in its cell surface expression decline [64] .
Hypothetically, accumulation of this faulty protein in the ER proceeds until such point when its levels rise above threshold leading to the activation of the UPR. In fact, using a cell line model system genetically manipulated to express either HFE wt or HFE C282Y, higher levels of specific UPR markers were observed in those cells expressing the mutant protein [64]. Significantly, ex vivo PBMCs from HFE C282Y homozygous HH patients recapitulated this result establishing the UPR activation as a putative modifier of HH, taking into account its decisive role on the progression of several other diseases. Considering the numerous intracellular events modified by the UPR signallingpathway, it was tempting to consider that the UPR might mediate the HFE/MHC-I cross-talk. Actually, induction of the UPR, either pharmacologically or by the transfection of HFE C282Y, results in a significant down-regulation of the MHC-I cell surface expression. Moreover, inhibition of the ER stress response in cells expressing the HFE C282Y mutant protein leads to the restoration of the MHC-I levels
The broad impact of the UPR on distinct cellular mechanisms, combined with the complexity of the antigen presentation pathway, does not make the establishment of a mechanistic link between the ER stress response activation and the MHC-I impairment an easy task. However, in light of some processes known to participate in both pathways, it is possible to envisage some plausible reasons for the MHC-I deficiency. As part of the struggle to relieve the folding pressure launched upon the ER, activation of the UPR promotes protein trafficking from and beyond this compartment through the induction of cargo receptors [65, 66] . The lectin ERGIC-53, a cargo receptor for the ER export of proteins and its related protein VIP36 are known targets of the UPR signallingpathway [66] . The premature removal of ER clients in situations of stress may have a significant impact on proteins relying on a dedicated quality control mechanism to achieve a stable conformation. MHC-I molecules depend on the PLC to promote the assembly of low off-rate MHC-I/peptide complexes before their journey through the standard secretory pathway [32] . This ensures that only complexes with superior stability are produced and delivered to the final destination. The extent of this peptide loading (nATF6) [77] and to enhance the secretion of the mutant (1-antitrypsin Z protein [78] . Endogenous bile acids derivatives, such as TUDCA, can also modulate ER function protecting from UPR induction and ER stress-induced apoptosis [79, 80] . Recently, these chemical chaperones were shown to improve glucose tolerance and insulin action in a mouse model of type 2 diabetes [80] . Moreover, TUDCA is already applied as a hepatoprotective agent in humans with cholestatic liver diseases [81, 82] , while 4PBA has been in clinical use in trials for treatment of thalassaemia [83] .
The finding that an UPR is activated in HH [64] has motivated the investigation of the effect of these promising pharmacologically active compounds in the modulation of the stress response. In fact, both TUDCA and 4PBA impeded the UPR activation in HFE C282Y expressing cells [5, 84] . Moreover, chemically enhancing the ER function using 4PBA also prevented the formation of intracellular protein aggregates by facilitating the degradation of HFE C282Y [5] 
